A survey of the impact of COVID-19 on the prescription and other conditions of patients with gastrointestinal diseases
- Conditions
- gastrointestinal ulcer, reflux esophagitis, chronic constipation, ulcerative colitis , Crohn's disease, and hepatic cirrhosis
- Registration Number
- JPRN-UMIN000041705
- Lead Sponsor
- EA Pharma Co.,Ltd.
- Brief Summary
About 20% of eligible patients reduced their visit and 70% of them had not restored the f requency of visits. Their symptoms changed m ore widely than those who not. We identified longer duration of disease and higher medica l adherence score as the factors not reducin g visits. Few patients used telemedicine. A quarter of patients were recording their sy mptoms and they had higher medical adherence score.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 650
Not provided
1. Patients who did not report any use of drugs for gastrointestinal diseases at the past survey 2. Patients who reported any cancer at the past survey 3. Patients who work for any of the following organizations - market research companies - media companies - advertising companies - hospitals or clinics - pharmaceutical companies - pharmaceutical wholesalers 4. Patients whose family members work for any of the above organizations
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The interval, amount, and days of prescriptions for medications of gastrointestinal diseases
- Secondary Outcome Measures
Name Time Method EQ-5D J-HLS-EU-Q47 Adherence scale for patients with chronic disease